SEC Form 4 · accession 0000899243-19-006649
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tony W Ho
Officer — See Remarks
Period of report
Mar 5, 2019
Accepted (ET)
Mar 7, 2019 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | Mar 5, 2019 | A | 10,000 | $40.87 | A | 32,869 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $40.87 | Mar 5, 2019 | A | 75,000 | A | — | Mar 5, 2029 | Common Shares | 75,000 | 75,000 | D |
Explanation of responses
- F1This restricted stock unit award was granted on March 5, 2019 with respect to 10,000 Common Shares, with (i) 3,333 shares vesting on March 5, 2020, (ii) 3,333 shares vesting on March 5, 2021, and (iii) 3,334 shares vesting on March 5, 2022. Each restricted stock unit represents a contingent right to receive one CRSP Common Share.
- F2This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019.
Remarks
Executive Vice President, Head of Research & Development